This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acute myocardial infarction급성 심근경색증

Contents and key points
ItemDetails
A. Classification codesICD-10: I21 (acute myocardial infarction) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsST-segment elevation myocardial infarction (STEMI, I21.0-I21.2), non-ST-segment elevation myocardial infarction (NSTEMI, I21.4), heart attack, coronary artery occlusion, part of acute coronary syndrome (ACS)
C. Adult onsetAcute myocardial infarction occurs mainly in people in their 50s to 70s, and men develop it about 10 years earlier than women. When risk factors such as smoking, diabetes and hypertension accumulate, it also occurs in people in their 40s or younger.
1. History1912: Herrick first described the association between coronary thrombosis and myocardial infarction. 1960s: introduction of the CCU; 1977: Gruentzig's PTCA. 2000s: drug-eluting stents; shift from thrombolytics → the era of primary PCI.
2. CausesCoronary atherosclerotic plaque rupture/erosion → thrombus formation → complete occlusion (Type 1 MI). Oxygen supply-demand imbalance (Type 2: anemia, bradycardia, spasm, etc.). Rarely spasm, embolism, dissection, vasculitis.
3. GeneticsHeritability of CAD 40–60%. GWAS have identified more than 100 risk loci, including 9p21.3 and PCSK9. Familial hypercholesterolemia (FH): LDLR, APOB and PCSK9 variants cause premature MI.
4. General epidemiologyAbout 9 million cases per year worldwide. About 50,000–60,000 people per year in Korea. 30-day in-hospital mortality reduced to 4–7% in the primary PCI era. Male predominance; increasing burden in older people and in low- and middle-income countries.
5. PathophysiologyUnstable plaque rupture → platelet activation/aggregation → thrombus → complete coronary occlusion → myocardial ischemia/necrosis (20 minutes or longer). STEMI: complete occlusion. NSTEMI: partial occlusion. Reperfusion injury (reactive oxygen species, mitochondrial dysfunction).
6. SymptomsSevere precordial pressure, tightness or tenderness (20 minutes or longer, unresponsive to rest). Radiation to the left arm, shoulder and jaw. Diaphoresis, nausea, dyspnea. Atypical: epigastric pain, fatigue, syncope (women, older adults, diabetic patients).
7. SignsDiaphoresis/pallor, tachycardia, hypotension (in cardiogenic shock), new heart murmur (acute MR, VSD), pulmonary edema (crackles), jugular venous distension (in right ventricular infarction). The Killip classification grades the severity of heart failure.
8. ScreeningImmediate 12-lead ECG in patients with precordial pain (within 10 minutes). High-sensitivity troponin 0/1-hour (or 0/2-hour) protocol. Risk stratification with the HEART score.
9. DiagnosisSTEMI: ST elevation in ≥2 contiguous leads on 12-lead ECG. NSTEMI: troponin elevation + ischemic symptoms. Coronary angiography (CAG) to confirm the anatomy. Echocardiography to assess wall motion abnormalities and complications.
10. TreatmentSTEMI: target primary PCI within 120 minutes of symptom onset. If not possible, thrombolysis → transfer for PCI. NSTEMI: dual antiplatelet + anticoagulation + early invasive strategy. Early administration of beta-blockers, statins and ACE inhibitors.
11. Prognosis30-day in-hospital mortality: STEMI ~5%, NSTEMI ~3~5%. 1-year mortality 10–15%. Killip IV (cardiogenic shock) mortality 40–60%. Preservation of left ventricular function is key to long-term prognosis.
12. PreventionPrimary prevention: management of cardiovascular risk factors (smoking cessation; control of blood pressure, blood glucose and cholesterol). Secondary prevention: DAPT + statin + ACE inhibitor + beta-blocker + cardiac rehabilitation.
13. References2023 ESC Guidelines for the management of acute coronary syndromes … and 9 other papers

1. History

The clinical understanding of acute myocardial infarction (AMI) began in 1912, when the American James Herrick first clearly described the association between coronary thrombosis and myocardial infarction. He explained the phenomenon then often understood in clinical practice as 'sudden cardiac death' as myocardial necrosis caused by coronary artery occlusion, and this concept gradually took hold in clinical medicine over the following decades. Autopsy studies by pathologists of the same era supported this association.

In the 1960s, the coronary care unit (CCU) was introduced, making ECG monitoring and immediate defibrillation possible for patients with myocardial infarction. This dramatically reduced mortality from arrhythmias in the acute phase. During this period, clinical use of thrombolytics such as streptokinase was attempted, making it possible to recanalize occluded coronary arteries. The success of Andreas Gruentzig's percutaneous transluminal coronary angioplasty (PTCA) in 1977 marked the turning point from the era of thrombolysis to the era of mechanical reperfusion.

With the introduction of stents in the 1990s and the development of drug-eluting stents (DES) in the 2000s, the outcomes of percutaneous coronary intervention (PCI) improved greatly. 'Primary PCI' was established with the goal of being performed in STEMI patients within 90 minutes of hospital arrival (or within 120 minutes of first medical contact), and as a result 30-day in-hospital mortality fell from over 10% to under 5%. The accumulation of large-scale data through global registries (GRACE, TIMI studies, etc.) contributed to risk stratification and the optimization of treatment strategies.

The 2023 European Society of Cardiology (ESC) guidelines on acute coronary syndromes comprehensively updated the use of the high-sensitivity troponin 0/1-hour protocol, the early invasive strategy in NSTEMI, the choice of P2Y12 inhibitor (ticagrelor or prasugrel preferred), anticoagulation strategy, and drug therapy after reperfusion.


2. Causes

The most common cause of acute myocardial infarction is Type 1 MI, in which abrupt rupture or erosion of an atherosclerotic plaque leads to thrombus formation that completely or nearly completely occludes a coronary artery. Unstable plaques are characterized by a thin fibrous cap, a lipid-rich core, and numerous inflammatory cells (macrophages, T cells), and they can suddenly open as a result of hemodynamic shear stress, internal spasm, or spontaneous rupture. Rapid activation and aggregation of platelets form the occlusive thrombus.

Type 2 MI is myocardial necrosis caused by an imbalance between myocardial oxygen supply and demand, without rupture of an atherosclerotic plaque in the coronary artery itself. Causes include severe anemia, hypotension, tachycardia, hypertensive crisis, coronary vasospasm, aortic stenosis and cocaine use. Other rare causes include coronary embolism (intra-atrial thrombus due to atrial fibrillation, thrombus from a prosthetic heart valve), coronary artery dissection (spontaneous coronary artery dissection, SCAD; especially in young women), coronary vasculitis (a complication of Kawasaki disease), and collagen vascular disease.


3. Genetics

The genetics of acute myocardial infarction follows the same context as the genetics of coronary artery disease (CAD). The heritability of CAD is about 40–60%, and a family history of premature coronary artery disease in a first-degree relative (onset before age 55 in men and before age 65 in women) raises the risk of MI about 2- to 3-fold. Among the risk loci discovered in large GWAS, variants in the 9p21.3 region (near CDKN2A/B) independently increase CAD risk by 25–40%, acting through a pathway unrelated to LDL cholesterol or blood pressure.

Familial hypercholesterolemia (FH) is the most important single genetic cause of premature myocardial infarction. Heterozygous loss-of-function variants in the LDLR (LDL receptor) gene (prevalence ~1/200~500) keep LDL-C at 190mg/dL or higher, and if untreated, the risk of myocardial infarction before age 50 in men and before age 60 in women is tens of times higher than in the general population. Polygenic risk scores (PRS) are increasingly used clinically, combined with traditional clinical risk scores, as a tool to identify high-risk individuals.


4. General epidemiology

Acute myocardial infarction occurs in more than about 9 million cases per year worldwide and is a leading cause of death from cardiovascular disease. In Korea, about 50,000–60,000 patients develop acute myocardial infarction each year, and the annual incidence based on health insurance claims data is on a continuing upward trend. Rising prevalence of the major risk factors obesity and diabetes, together with population aging, are the main drivers of the rising incidence.

Men develop myocardial infarction about 10 years earlier than women, but the incidence in women rises sharply after age 65, so the sex difference narrows in older age. Atypical symptoms (nausea, fatigue, epigastric pain) are common in women, and diagnosis tends to be delayed. Mortality from myocardial infarction is relatively higher in low- and middle-income countries, owing to limited access to health care, a lack of primary PCI facilities, and limited access to secondary prevention drugs. With the widespread adoption of primary PCI, 30-day in-hospital mortality in developed countries has fallen markedly from over 30% in the 1960s to 4–7% today.


5. Pathophysiology

The pathophysiology of STEMI (ST-segment elevation myocardial infarction) is complete occlusion of a coronary artery caused by abrupt rupture of an unstable atherosclerotic plaque. When platelets rapidly aggregate at the site of plaque rupture and the coagulation cascade is activated to form a fibrin thrombus, coronary blood flow is completely blocked. If myocardial ischemia lasts 20 minutes or longer, irreversible myocardial necrosis (myocardial infarction) begins and spreads within 6 hours from the subendocardium to the full thickness of the wall (transmural). The area of myocardial necrosis appears on the ECG as ST-segment elevation and Q-wave formation.

The pathophysiology of NSTEMI is partial occlusion of a coronary artery (the thrombus does not completely block the vessel, or there is spontaneous recanalization after transient complete occlusion). In this case myocardial injury occurs and troponin rises, but there is no ST-segment elevation. Reperfusion injury is also an important mechanism: when the coronary artery is recanalized, additional myocardial injury occurs through oxidative stress (reactive oxygen species), calcium overload, opening of the mitochondrial permeability transition pore (mPTP), and cell death (apoptosis, necroptosis). This reperfusion injury is estimated to account for about 50% of the final infarct size.


6. Symptoms

The typical symptom of acute myocardial infarction is severe pressure, tightness, heaviness or burning in the precordium, which, unlike angina, persists even at rest (20 minutes or longer) and is not relieved by nitroglycerin. The pain may radiate to the left shoulder, arm (especially the inner side), neck, jaw and back. Diaphoresis (cold sweat), nausea, vomiting and dizziness are commonly accompanying, and in severe cases dyspnea and decreased consciousness also occur.

Atypical symptoms are more common in women, older adults (75 years or older) and diabetic patients. In these cases, epigastric pain, indigestion, extreme fatigue, dyspnea and syncope may be the main symptoms rather than chest pain, so diagnosis is easily delayed. 'Silent MI' occurs without pain in diabetic and older patients and is discovered later on ECG or echocardiography. Right ventricular infarction shows a distinctive clinical picture of chest pain together with hypotension, jugular venous distension, and shock without pulmonary edema.


7. Signs

On physical examination of patients with acute myocardial infarction, diaphoresis, pallor, restlessness, tachycardia (or bradycardia: vagal hyperactivity in inferior wall infarction) and blood pressure abnormalities (initial elevation, or a fall in cardiogenic shock) are observed. The Killip classification is a tool that predicts prognosis based on signs of heart failure: Killip I (no heart failure, 30-day mortality ~6%), II (S3 gallop or mild pulmonary rales, ~17%), III (frank pulmonary edema, ~38%), IV (cardiogenic shock, 40–60%).

If a new heart murmur develops, a serious mechanical complication should be suspected. A holosystolic murmur suggests acute mitral regurgitation due to papillary muscle dysfunction or rupture, and a new systolic murmur (at the left lower sternal border or the apex) suggests the possibility of ventricular septal defect (VSD). These two complications are life-threatening emergencies. Right ventricular infarction shows a characteristic picture of jugular venous distension and Kussmaul's sign without pulmonary edema.


8. Screening

The key to screening for the early diagnosis of acute myocardial infarction is performing an immediate 12-lead ECG (interpreted within 10 minutes) in every patient with precordial pain or atypical ischemic symptoms. STEMI is diagnosed by ECG alone, and the revascularization pathway is activated immediately. For differentiating NSTEMI and unstable angina, the 0-hour/1-hour (or 2-hour) protocol for high-sensitivity cardiac troponin (hs-cTn) has become the standard.

The HEART score (5 items: history, ECG, age, risk factors, troponin) is used in the emergency department for early risk stratification of chest pain patients and to judge the possibility of early discharge. Low-risk patients with a HEART score of 0–3 can safely be considered for early discharge. In high-risk patients (HEART ≥7 or elevated troponin), immediate specialist cardiology evaluation and an invasive approach are recommended.


9. Diagnosis

Diagnosis of STEMI is made when, together with typical ischemic symptoms, the 12-lead ECG shows ST-segment elevation at the J point in ≥2 contiguous leads (≥1mm in limb leads, ≥2mm in precordial leads, or in V2~V3 ≥2.5mm in men and ≥1.5mm in women). New left bundle branch block (LBBB) is also treated as equivalent to STEMI, with immediate revascularization.

Diagnosis of NSTEMI is made by ischemic symptoms + elevated high-sensitivity troponin (above the 99th percentile of the sex-specific reference value, or a significant rise within 1–2 hours), and is characterized by the absence of ST-segment elevation. Coronary angiography (CAG) is performed for anatomical confirmation and immediate PCI, with a target in STEMI of within 90 minutes of hospital arrival (within 120 minutes from medical contact to reperfusion). Echocardiography is essential for assessing left ventricular function, wall motion abnormalities and mechanical complications (VSD, acute MR, free wall rupture). CMR (cardiac MRI) accurately assesses myocardial viability, infarct size and the extent of reperfusion injury.


10. Treatment

Treatment of STEMI: the goal is coronary recanalization as quickly as possible. Primary PCI (primary percutaneous coronary intervention) aims to achieve balloon inflation within 120 minutes of medical contact; if this is not possible, thrombolysis (tenecteplase, alteplase) is given within 10 minutes, followed by transfer to a PCI-capable center. Before primary PCI, a loading dose of aspirin 300mg + a P2Y12 inhibitor (ticagrelor 180mg or prasugrel 60mg) is given, and an anticoagulant (heparin or bivalirudin) is used during the procedure.

Treatment of NSTEMI/unstable angina: dual antiplatelet therapy (aspirin + P2Y12 inhibitor) + anticoagulant (heparin, enoxaparin or fondaparinux). An immediate invasive strategy within 2 hours is used in the high-risk group (troponin elevation, hemodynamic instability, recurrent ischemia, GRACE score >140), and an early invasive strategy within 24 hours in the intermediate-risk group. Beta-blockers, high-intensity statins and ACE inhibitors/ARBs are started before discharge, and an aldosterone antagonist (eplerenone) is added when LVEF ≤40%.


11. Prognosis

In the primary PCI era, 30-day in-hospital mortality for STEMI has improved to about 4–7% in developed countries, and is about 3–5% for NSTEMI. However, with accompanying cardiogenic shock (Killip IV), 30-day mortality reaches 40–60% and the prognosis is very poor. One-year mortality for AMI overall is about 10–15%, after which an annual mortality of about 3–5% persists. Left ventricular ejection fraction (LVEF), infarct size, age, renal function and the presence of diabetes are the key determinants of long-term prognosis. Mechanical complications (ventricular septal defect, papillary muscle rupture, free wall rupture) are rare but fatal and require immediate surgical or mechanical circulatory support.


12. Prevention

Primary prevention: smoking cessation, regular physical activity, a Mediterranean diet and maintaining a normal body weight are the basics. Control of hypertension (target <130/80mmHg), treatment of dyslipidemia (LDL-C <70mg/dL in the high-risk group, <55mg/dL in the very-high-risk group) and glycemic control (HbA1c around <7% in diabetic patients) are the key pharmacological prevention strategies. When familial hypercholesterolemia is identified, high-intensity statins and PCSK9 inhibitors are started early.

Secondary prevention: after AMI, dual antiplatelet therapy (aspirin + ticagrelor or prasugrel, 12 months) is maintained. High-intensity statins (target LDL-C <55mg/dL), beta-blockers (with reduced LVEF or symptomatic heart failure) and ACE inhibitors/ARBs (with LVEF ≤40%, hypertension, diabetes or chronic kidney disease) are started early and continued. Cardiac rehabilitation programs are effective in reducing recurrent cardiovascular events, improving exercise tolerance and improving quality of life.


13. References

  1. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. PMID: 37622654.

  2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018;39(2):119-177. DOI: 10.1093/eurheartj/ehx393. PMID: 28886621.

  3. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology. 2018;72(18):2231-2264. DOI: 10.1016/j.jacc.2018.08.1038. PMID: 30153967.

  4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. PMID: 12517460.

  5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine. 2009;361(11):1045-1057. DOI: 10.1056/NEJMoa0904327. PMID: 19717846.

  6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine. 1992;327(10):669-677. DOI: 10.1056/NEJM199209033271001. PMID: 1386652.

  7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine. 1999;341(10):709-717. DOI: 10.1056/NEJM199909023411001. PMID: 10471456.

  8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. PMID: 28304224.

  9. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clinical Investigation. 2013;123(1):92-100. DOI: 10.1172/JCI62874. PMID: 23281415.

  10. Anderson JL, Morrow DA. Acute myocardial infarction. New England Journal of Medicine. 2017;376(21):2053-2064. DOI: 10.1056/NEJMra1606915. PMID: 28538121.